

115TH CONGRESS
2D SESSION

H. R. 1660

IN THE SENATE OF THE UNITED STATES

JANUARY 19, 2018

Received; read twice and referred to the Committee on Foreign Relations

AN ACT

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Global Health Innova-
3 tion Act of 2017”.

4 **SEC. 2. ANNUAL REPORT.**

5 (a) IN GENERAL.—Not later than 180 days after the
6 date of the enactment of this Act, and annually thereafter
7 for a period of 4 years, the Administrator of the United
8 States Agency for International Development shall submit
9 to Congress a report on the development and use of global
10 health innovations in the programs, projects, and activities
11 of the Agency.

12 (b) MATTERS TO BE INCLUDED.—The report re-
13 quired by subsection (a) shall include the following:

14 (1) A description of—

15 (A) the extent to which global health inno-
16 vations described in subsection (a) include
17 drugs, diagnostics, devices, vaccines, electronic
18 and mobile health technologies, and related be-
19 havior change and service delivery innovations;

20 (B) how innovation has advanced the
21 Agency’s commitments to achieving an HIV/
22 AIDS-free generation, ending preventable child
23 and maternal deaths, and protecting commu-
24 nities from infectious diseases, as well as
25 furthered by the Global Health Strategic
26 Framework;

1 (C) how goals are set for health product
2 development in relation to the Agency’s health-
3 related goals and how progress and impact are
4 measured towards those goals;

5 (D) how the Agency’s investments in inno-
6 vation relate to its stated goals; and

7 (E) progress made towards health product
8 development goals.

9 (2) How the Agency, both independently and
10 with partners, donors, and public-private partner-
11 ships, is—

12 (A) leveraging United States investments
13 to achieve greater impact in health innovation;

14 (B) engaging in activities to develop, ad-
15 vance, and introduce affordable, available, and
16 appropriate global health products; and

17 (C) scaling up appropriate health inno-
18 vations in the development pipeline.

19 (3) A description of collaboration and coordina-
20 tion with other Federal departments and agencies,
21 including the Centers for Disease Control and Pre-
22 vention, in support of global health product develop-
23 ment, including a description of how the Agency is
24 working to ensure critical gaps in product develop-
25 ment for global health are being filled.

1 (4) A description of how the Agency is coordi-
2 nating and aligning global health innovation activi-
3 ties between the Global Development Lab, the Cen-
4 ter for Accelerating Innovation and Impact, and the
5 Bureau for Global Health.

Passed the House of Representatives January 18,
2018.

Attest:

KAREN L. HAAS,

Clerk.